***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 JANUARY 2025**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Hypromellose with carbomer 980 | The sponsor requested the delisting of Genteal® gel(hypromellose with carbomer 980) and HPMC PAA (hypromellose with carbomer 980) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted there are multiple alternative lubricating eye gel products available. The PBAC advised the delisting of these products would not result in an unmet clinical need. |

Brendon Wheatley

Director (A/g), PBAC Governance

Office of Health Technology Assessment

Technology Assessment and Access Division

06 December 2024